• LAST PRICE
    2.3600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 2.3600
  • Day Range
    ---
  • 52 Week Range
    Low 1.9400
    High 16.9490
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.56
TimeVolumeIKNA
10:24 ET4002.42
10:26 ET2002.39
10:29 ET4002.43
10:51 ET5002.4422
10:54 ET1002.5
12:06 ET23892.19
12:08 ET2002.46
12:10 ET2002.47
12:19 ET1002.47
12:51 ET1002.48
12:55 ET1002.48
12:57 ET4322.48
01:00 ET9702.36
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIKNA
Ikena Oncology Inc
85.6M
-1.6x
---
United StatesPIRS
Pieris Pharmaceuticals Inc
74.4M
-2.1x
---
United StatesFIXX
Homology Medicines Inc
89.1M
-16.9x
---
United StatesSTTK
Shattuck Labs Inc
97.1M
-1.4x
---
United StatesCLSD
Clearside Biomedical Inc
71.0M
-11.7x
---
United StatesSQZ
SQZ Biotechnologies Co
78.0M
-1.0x
---
As of 2022-11-28

Company Information

Ikena Oncology, Inc. is a targeted oncology company, which develops medicines for patient groups with specific unmet needs. The Company lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also combining IK-930 with other targeted therapies across several indications, including EGFR mutated non-small cell lung cancer and KRAS mutated cancers. The Company has initiated a first in human Phase I clinical trial of IK-930 in patients with advanced solid tumors with a high frequency of Hippo pathway alternations. Its clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment. IK-175 is an oral inhibitor of aryl hydrocarbon receptor, which it is evaluating in a Phase Ia/Ib clinical trial in solid tumors and in urothelial carcinomas as monotherapy and in combination with nivolumab.

Contact Information

Headquarters
50 Northern Ave.BOSTON, MA, United States 02210
Phone
857-343-8292
Fax
302-655-5049

Executives

Independent Chairman of the Board
Ronald Renaud
President, Chief Executive Officer, Director
Mark Manfredi
Chief Financial Officer, Head of Corporate Development
Jotin Marango
Acting Principal Accounting Officer
Francisco Olivera
Chief Scientific Officer
Michelle Zhang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$85.6M
Revenue (TTM)
$30.4M
Shares Outstanding
36.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.43
Book Value
$5.78
P/E Ratio
-1.6x
Price/Sales (TTM)
2.8
Price/Cash Flow (TTM)
---
Operating Margin
-174.42%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.